More News

Repka Plans to Use AAO Presidency to Push for Medicare Payment Reform

Michael X. Repka, MD, MBA, the new president of the American Academy of Ophthalmology, plans to make Medicare payment reform his top priority during his one-year term. Medicare reimbursement to US ...

Health Canada Approves Rayner’s RayOne EMV Toric IOL

UK-based Rayner announced Jan. 21 that Health Canada had approved the toric version of its RayOne EMV enhanced monofocal intraocular lens (IOL). The non-toric version of the lens was approved in Ca...

Inventors of OCT to be Inducted Into National Inventors Hall of Fame

The inventors of optical coherence tomography continue to be recognized for their groundbreaking work. James G. Fujimoto, PhD (Massachusetts Institute of Technology), David Huang, MD, PhD (Oregon H...

2024 in Review: Zeiss' Rollout of Micor 700 Shakes Up Cataract Equipment Market in US

German company Carl Zeiss Meditec’s US launch of its Micor 700 handpiece for cataract surgery in 2024 represented a significant step forward in innovation. The Micor offers an entirely new way to s...

Formycon, Klinge Gain EU Approval for Eylea Biosimilar Under Brand Names Ahzantive and Baiama

German companies Formycon and Klinge Biopharma announced Jan. 20 that the European Commission had granted marketing authorization for their Eylea biosimilar, under the brand names Ahzantive and Bai...

Arctic Vision Gains Approval of Arcatus (Xipere) for Uveitic Macular Edema in Australia, Singapore

Clearside Biomedical announced Jan. 22 that its Asia-Pacific partner, Arctic Vision, had gained approval in Australia and Singapore for Arcatus, known as Xipere in the US, for uveitic macular edema...

Senju Files for Marketing Approval of Dry Eye Candidate SJP-0132 in Japan

Japan’s Senju Pharmaceutical announced Jan. 17 that it had submitted a marketing application in Japan for SJP-0132, a TRPV1 antagonist eye drop candidate targeting dry eye. TRPV1 antagonists have a...

Ophthalmology Sees $6.3 Billion in Total Investment in 2024, With 18 M&A Transactions

The ophthalmic market continues to expand and attract funding from a wide variety of investors. Total amounts raised in 2024 reached over $6.3 billion. Venture capital investment in ophthalmology i...

Bausch Kicks off 2025 With Series of Research Deals, Plus an IOL Launch

Bausch + Lomb has recently announced a series of acquisitions and collaborations that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. It also launched an ...

Select US FDA Approvals and Clearances in December 2024

The US FDA granted four clearances through the ophthalmic device division using the 510(k) pathway in December 2024, according to the agency’s database. AI Optics gained clearance for its Sentinel ...

Glaukos Submits NDA for Epioxa Epi-On Crosslinking Treatment

Glaukos, of Aliso Viejo, California, reported Dec. 23 that it had submitted its new drug application to the US FDA for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy,...

US FDA PDUFA Dates for Ophthalmic Drug Candidates

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.

Aviceda Leads Latest Ophthalmic Fundraising with $207.5 Million Round

Aviceda Therapeutics led recent ophthalmic fundraising efforts with an upsized $207.5 million Series C financing round to support its trials in geographic atrophy. Financing announced in the past f...

2024 in Review: Corporate and Surgeon Rankings of Top 10 Stories

Market Scope asked industry participants and surgeons to select the top story for 2024. Below are their choices. Zeiss’ Rollout of Micor 700 Shakes Up Cataract Equipment Market in US MAC Turmoil Sh...

2024 in Review: MAC Turmoil Shakes Out with Final Policy on Coverage of MIGS

Five of the seven US Medicare Contract Administrators ended a two-year roller coaster ride for the glaucoma surgery market in mid-November by publishing for the second time their final coverage pla...

2024 in Review: Newest PC-IOLs Helped Drive Worldwide Growth in 2024

At least a dozen trifocal and EDOF IOLs were launched in key markets over the past 18 months, spurring worldwide growth and giving presbyopia-correcting lenses a small uptick in their market share ...

2024 in Review: Alcon Expands Its Glaucoma Portfolio With Belkin Acquisition

Alcon completed its acquisition of Israel’s Belkin Vision, maker of the Eagle laser for glaucoma, in July 2024. The purchase expands Alcon’s presence in the glaucoma market; Alcon also offers the H...

$2024 in Review: SMILE for Hyperopia, Two Excimer Lasers Lead Refractive Surgical News$

2024 in Review: SMILE for Hyperopia, Two Excimer Lasers Lead Refractive Surgical News

Bausch + Lomb announced in January 2024 that the US FDA had approved the Teneo excimer laser platform for LASIK for myopia and myopic astigmatism. It’s the first excimer platform approved in the US...

2024 in Review: LumiThera’s Valeda is First Treatment for Early, Intermediate Dry AMD

The US FDA granted market authorization to LumiThera’s Valeda Light Delivery System as a de novo device on Nov. 4, making it the first treatment of any kind, device or drug, to receive the FDA’s ba...

2024 in Review: Flurry of Eylea Biosimilars Approved; Most Blocked in US by Lawsuits

The FDA was in a hurry in 2024 to get low-cost competitors to Eylea into the US market. Regeneron wasn’t. The FDA approved 12 drugs for ophthalmic indications in 2024, including four generic glauco...

2024 in Review: Change Healthcare and Hoya Data Breaches Highlight Security Risks

The health care and public health sector was the most common ransomware target of any critical US infrastructure sector in 2023 and 2024, according to the FBI. By October 2024, the American Hospita...

2024 in Review: Complement Therapies for GA Fall Short in Bid for Approval in EU

Apellis Pharmaceuticals and Astellas Pharma were unable to build on their regulatory wins in the US to get a victory in Europe. The European Medicines Agency’s Committee for Medicinal Products for ...

2024 in Review: Warburg Pincus Buys Controlling Stake in India’s Appasamy

US-based private equity firm Warburg Pincus re-entered the ophthalmic industry in April 2024 when it bought a controlling stake in India’s Appasamy Associates. Financial details were not disclosed,...

Clinical Trial Updates for Ophthalmic Candidates, January 2025

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

EssilorLuxottica to Acquire Ophthalmic Device Maker Espansione Group

Eyewear conglomerate EssilorLuxottica announced Dec. 16 that it had entered into an agreement to acquire Espansione Group, an Italian maker of light-based ophthalmic devices. Financial details and ...

Carter’s Many Accomplishments Include Saving Millions from Blindness

Former US president Jimmy Carter’s many legacies include saving the of sight of millions of people in less developed regions by providing treatment for onchocerciasis and trachoma through his Carte...

Children’s Hospital Los Angeles Celebrates 100th Luxturna Procedure

Children’s Hospital Los Angeles (CHLA) marked a milestone recently, completing its 100th procedure with the retinal gene therapy Luxturna for Leber congenital amaurosis (LCA)—the most of any center...

2025-2026 Ophthalmic Meetings Calendar

Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.

Emerging Companies Pursuing Ophthalmic Indications, January 2025

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

Weekly Surgeon Poll, January 2025

Johns Hopkins Scientists Develop Clear OVD That Glows Under Blue Light

Scientists at Johns Hopkins University have developed a clear ophthalmic viscosurgical device (OVD) that turns fluorescent green under blue light, allowing surgeons to verify complete removal of th...

January 2025 Ophthalmic News Briefs

China’s Eyebright Medical announced Jan. 7 that its phakic intraocular lens, the Loong Crystal PR, had received certification as a Class III medical device from the country’s National Medical Produ...

Bausch + Lomb Moves to Acquire Whitecap, InflammX to Expand Clinical Pipeline

Bausch + Lomb recently made moves to acquire two companies that it says will strengthen its expanding pipeline and help address unmet needs in ophthalmology. The company announced Jan. 13 that an a...

Dual Inflammasome Inhibiting Implant Shows Positive Phase I/II Results in GA

Inflammasome Therapeutics reported on Jan. 15 positive topline three-month data from a Phase I/II trial of its K8 dual inflammasome inhibiting implant in geographic atrophy (GA). In the study of fi...

Study Shows Promise for Genetic Base Editing in Stargardt Disease

Researchers from Switzerland’s Institute of Molecular and Clinical Ophthalmology Basel and Beam Therapeutics say they have developed a gene editing therapy that could potentially treat Stargardt di...

Tarsus Will Advance Lotilaner Eyelid Gel for Ocular Rosacea

Tarsus Pharmaceuticals, of Irvine, California, announced Jan. 13 that it would advance TP-04, an ophthalmic gel formulation of lotilaner, targeting ocular rosacea. Tarsus, maker of Xdemvy eye drops...

Bausch + Lomb to Collaborate with Character Bio, City Therapeutics in AMD, GA

Bausch + Lomb recently made deals to collaborate with two companies that it says will bolster its expanding pipeline and help address unmet needs in ophthalmology. Character Biosciences reported on...

Bausch + Lomb Launches EnVista Aspire Monofocal-Plus IOLs in Europe

On Jan. 13, Bausch + Lomb announced the launch of its enVista Aspire intermediate-optimized monofocal and toric intraocular lenses, often referred to as monofocal-plus IOLs, in the EU. The IOLs lau...

Teva Signs Deal to Commercialize Formycon’s Aflibercept Biosimilar Candidate in Israel and Most of Europe

Israel’s Teva Pharmaceuticals announced Jan. 13 that it had entered into a collaboration with German companies Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Form...

Valo Health Suspends Work on Oral DR Candidate After Phase II Trial Misses Endpoints

Valo Health reported Dec. 31 that OPL-0401, its oral diabetic retinopathy treatment candidate, missed its primary and secondary endpoints of improvement in Diabetic Retinopathy Severity Scale score...

Aviceda Raises $207.5 Million in Upsized Series C Round to Advance GA Candidate

Aviceda Therapeutics announced Jan. 7 that it had raised $207.5 million in an upsized Series C funding round. The Cambridge, Massachusetts, company said proceeds would support an ongoing Phase IIb/...

Eyebright Medical Gains Certification in China for Phakic IOL

Low-Vision Devices, Including One Similar to a Fly’s Eye, Highlighted at CES 2025

The 2025 Consumer Electronics Show featured at least two wearable devices intended to improve vision for those who are vision impaired or legally blind. The conference was held Jan. 7-10 in Las Veg...

US FDA Grants Rare Pediatric Disease Designation to ViGeneron’s RP Gene Therapy Candidate

Germany’s ViGeneron announced Jan. 8 that the US FDA had granted rare pediatric disease designation to VG901, a gene therapy candidate targeting retinitis pigmentosa (RP) caused by mutations in the...

Eyenuk Appoints Gaurav Agarwal as Chief Executive Officer

Digital health care company Eyenuk, of Los Angeles, California, announced Jan. 6 that it had appointed Gaurav Agarwal as chief executive officer. Agarwal was previously the head of product and cust...

Unity Biotechnology Appoints Federico Grossi, MD, PhD, as Chief Medical Officer

Unity Biotechnology announced Jan. 6 that it had appointed Federico Grossi, MD, PhD, as chief medical officer. Grossi was most recently chief medical officer at Apellis Pharmaceuticals, where he he...

Xbrane Resubmits BLA to US FDA for Ranibizumab Biosimilar

Sweden’s Xbrane Biopharma announced Dec. 31 that it had resubmitted the biologics license application (BLA) to the US FDA for its Lucentis (ranibizumab) biosimilar candidate. The FDA issued a compl...

Ophthalmic Revenue Roundup for Carl Zeiss Meditec, Amgen, Biogen

Carl Zeiss Meditec reported Dec. 11 that ophthalmology revenue for its full fiscal year 2023/2024, which ended Sept. 30, was €1.59 billion (US $1.7 billion, converted Dec. 11, 2024), an increase of...

ViGeneron Gains US FDA Green Light to Begin Phase I/II Trial of Gene Therapy Candidate for Stargardt

Germany’s ViGeneron announced Dec. 18 that the US FDA had cleared its investigational new drug (IND) application for a Phase I/II study of VG801, a gene therapy candidate to treat Stargardt disease...

EssilorLuxottica to Acquire Espansione Group, Maker of Ophthalmic Devices

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.